DIRS.INFO The most relevant business & tech news

Morgan Stanley raised its price target on Netflix to $700 from $600. 7:13 a.m.: JPMorgan cuts Boeing price target, but says demand should push strong long-term growth Investors shouldn't give up on Boeing as a long-term investment, according to JPMorgan. Analyst Seth Seifman lowered his price target by $20 to $210, implying 21.1% potential upside for shares of the aerospace company. He raised his target price by $14 to $62, which suggests 4.2% potential upside for DocuSign over the next year. The analyst kept his neutral rating on the stock but cut his price target by $16 to $180.

Persons: Morgan Stanley, Seth Seifman, Seifman, — Pia Singh, Evan Seigerman, Seigerman, Karl Keirstead, DocuSign, Keirstead, Itay Michaeli, Michaeli, Tesla, Elon Musk, Benjamin Swinburne, Swinburne, Wolfe, Shreyas Patil, Patil, Fred Imbert Organizations: CNBC, Netflix, Wolfe Research, JPMorgan, Boeing, Novo Nordisk, BMO Capital Markets BMO Capital, pharma, UBS, Adobe, Citi, Citi Research, Tesla, Netflix Netflix, Mobileye Locations: China, Novo, U.S, Netflix's

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Most employer health plans don't cover new blockbuster weight loss drugs, but that's going to change
▼ + stars: | 2024-02-16 | by ( Cheryl Winokur Munk | ) www.cnbc.com time to read: +10 min

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Still, many benefits experts say it's a matter of when, not if, more employers will cover GLP-1 drugs. Certainly, prescription volumes of GLP-1 weight loss drugs are soaring. Even though GLP-1 drugs are high-priced, they currently represent only 6.9% of annual claims, according to data from the International Foundation of Employee Benefit Plans. It's going to be harder and harder not to cover these drugs because the benefits seem to be so great."

Persons: Eli Lilly, there's, Julie Stich, Eli Lilly's, Greg Stancil, you've, Stancil, somebody's, James Wantuck, " Stich, Brian O'Connell, O'Connell, Wantuck, Krutika Amin, Amin Organizations: U.S, Nordisk, International Foundation of Employee, Novo Nordisk, Tufts Medical, Medicare, Healthy Aging, Scott Benefit Services, Employers, Accolade, BMI, International Foundation of, Medicaid — Locations: U.S, KFF, North Carolina, GLP, Novo

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

Still, Eli Lilly and Novo Nordisk appear to be making some encouraging progress. Eli Lilly wasn't the only weight loss drug producer to see positive supply developments in the last week. Novo Holdings, which owns almost 77% of the voting shares in Novo Nordisk, said Monday it will acquire drug manufacturer Catalent in a $16.5 billion deal. Novo Nordisk will then buy three of Catalent's manufacturing plants from Novo Holdings for $11 billion. Tema in November launched an ETF whose key holdings include companies benefiting from the hype around weight loss drugs.

Persons: Eli Lilly, Anat Ashkenazi, Incretin, Eli Lilly's, Ashkenazi, Eli Lilly wasn't, Yuri Khodjamirian, Danish drugmaker Organizations: Novo Nordisk, Holdings, Wegovy, Novo Holdings, CNBC, Tema, Nordisk, Reuters Locations: North Carolina, Novo, Tema, Brussels, Danish, U.S

☆ The market is seeing red. But here's why a few of our portfolio stocks are standing out
▼ + stars: | 2024-02-05 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable update of the trading day, just in time for the last hour on Wall Street. "Microsoft is the one to buy first on weakness due to the quality of last week's quarter and outlook," Jim Cramer said Monday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jerome Powell's, Estee Lauder, Jim, Cramer, Eli Lilly, Lilly, Linde, Jim Cramer's, Brendan McDermid Organizations: CNBC, Federal, Nvidia, Apple, Microsoft, Sector, Technology, Semiconductor, Novo Nordisk, Air Products, Chemicals, Products, Linde, ., Vertex Pharmaceuticals, Simon Property Group, NXP Semiconductors, Club, GE Healthcare, DuPont, Carrier Global, Jacobs Solutions, Ford, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: We're, Novo, China, New York City, U.S

☆ Stocks making the biggest moves midday: Nvidia, Boeing, Snap, Tyson Foods and more
▼ + stars: | 2024-02-05 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

McDonald's posted adjusted earnings of $2.95 per share on $6.41 billion in revenue. Analysts had expected earnings of $2.82 per share and $6.45 billion in revenue, according to LSEG, formerly known as Refinitiv. Analysts polled by FactSet forecast earnings of $2.30 per share on $8.9 billion in revenue for the fourth quarter. The company posted adjusted earnings of 69 cents per share on revenue of $13.32 billion. Caterpillar reported adjusted earnings of $5.23 per share on revenue of $17.07 billion.

Persons: Goldman Sachs, McDonald's, Eli Lilly, Jim Umpleby, Estée Lauder —, Dali Rajic, —, Macheel, Jesse Pound, Hakyung Kim, Alex Harring, Michelle Fox, Sarah Min, Darla Mercado Organizations: Nvidia, Novo Nordisk —, Novo Holdings, Novo Nordisk, Management, U.S . Food, Boeing —, Boeing, Tyson, Caterpillar, Air Products, Chemicals, Reuters Locations: Novo, U.S

☆ Stocks making the biggest moves premarket: Estee Lauder, Nvidia, McDonald's, Caterpillar and more
▼ + stars: | 2024-02-05 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines before the bell: Estee Lauder — The cosmetics stock jumped 15% after Estee Lauder beat expectations with its latest results. In its second quarter, Estee Lauder reported adjusted earnings of 88 cents per share, topping the FactSet consensus estimate of 54 cents per share. Caterpillar — Shares of the heavy machinery maker popped more than 4% after the company reported adjusted earnings per share of $5.23 for the fourth quarter. In its first quarter, the industrial gas supplier reported adjusted earnings of $2.82 per share, weaker than earnings of $3.00 per share expected by analysts polled by StreetAccount. Stellantis — Stellantis shares slid 1.7% after Italian daily Il Messaggero , citing financial sources, reported the French government is reviewing a merger between Stellantis and Renault to compete with German and Chinese automakers, according to FactSet.

Persons: Estee Lauder, Catalent, Goldman Sachs, Il, McDonald's, — CNBC's Brian Evans, Michelle Fox, Fred Imbert, Hakyung Kim, Pia Singh Organizations: Novo Holdings, Caterpillar —, Revenue, North America . Air Products, Chemicals, Air Products, StreetAccount, JPMorgan, Nvidia —, Stellantis, Renault, McDonald's, Merck Animal Health, Mattel —, Warner Bros Locations: North America, StreetAccount .

☆ Morning Meeting rapid fire: Catalent, Snap, Cigna, McDonald's and Mattel
▼ + stars: | 2024-02-05 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMorning Meeting rapid fire: Catalent, Snap, Cigna, McDonald's and MattelJim Cramer runs through five stocks in the news Monday

Persons: Mattel Jim Cramer Organizations: Mattel

☆ Here are Jim Cramer's rapid-fire takes on 5 stocks in the news Monday
▼ + stars: | 2024-02-05 | by ( Paulina Likos | ) www.cnbc.com time to read: +1 min

Jim Cramer said this deal is Novo's way to "get more product" and addresses the "tremendous shortage" of these high-demand drugs. Shares of Eli Lilly , a stock in the CNBC Investing Club 's portfolio, were also up more than 4% ahead of Tuesday's earnings. Snap – The social media firm laid off 10% of its workforce ahead of Tuesday's earnings. Jim pointed out that Club name Starbucks (SBUX) has also been experiencing the same thing. Jim said buy McDonald's stock on weakness.

Persons: Jim Cramer, Eli Lilly, Lilly, Cramer, Cigna –, Cantor Fitzgerald, Jim Organizations: Nordisk, Catalent, CNBC, Microsoft, RBC Capital, Humana, Starbucks, Mattel –, JPMorgan, Vision, Apple Locations: Danish, Israel

☆ Comeback stocks: These names have jumped to start 2024 after falling last year
▼ + stars: | 2024-02-05 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

The Russell 1000 , which tracks the top 1,000 largest companies — large- and mid-cap names — is up about 3% in 2024. With this in mind, CNBC Pro screened for the stocks making a comeback in 2024. However, the consensus price target is just 4.6% from its current levels — putting into question whether there's more room for upside. Just 35.7% of analysts are bullish on the shares, and the average price target implies shares can grow just 4.3%. Sarepta Therapeutics has soared 27.4% this year — and it could jump 20.1% more according to its consensus price target, per LSEG.

Persons: Russell, they're, Merck's, Sarepta Organizations: CNBC Pro, Pharmaceutical, Merck, Verizon, Barclays, VZ, LSEG, Novo Nordisk, Sarepta Therapeutics Locations: Novo

☆ Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
▼ + stars: | 2024-02-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novo Nordisk will then buy three of Catalent's manufacturing sites from Novo Holdings for $11 billion. Novo Holdings owns almost 77% of the voting shares in Novo Nordisk. Novo Nordisk and Novo Holdings said they expect the acquisition of the plants and the broader deal to buy Catalent to close at the end of 2024. Novo Nordisk added that it expects its purchase to gradually help increase its filling capacity beginning in 2026. Under the terms of the deal, Novo Holdings will buy Catalent for $63.50 a share in cash, a premium of 16.5% to Catalent's closing price on Friday.

Persons: Catalent, Eli Lilly Organizations: Nordisk, Novo Holdings, Novo Nordisk's Wegovy, Novo Nordisk, Novo, Elliott Investment Management, U.S ., Reuters, CNBC PRO Locations: Novo, Italy, Belgium, Bloomington , Indiana, Denmark, France, U.S, Brussels

☆ Cramer's Lightning Round: 'Stay away' from Catalent
▼ + stars: | 2023-11-29 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Vishay Intertechnology's year-to-date stock performance. Stock Chart Icon Stock chart icon Abbott Laboratories' year-to-date stock performance. Stock Chart Icon Stock chart icon Anheuser-Busch's year-to-date stock performance. Stock Chart Icon Stock chart icon Catalent's year-to-date stock performance. Stock Chart Icon Stock chart icon Moelis & Company's year-to-date stock performance.

Persons: Vishay, you've, Lads, Jim Cramer's Organizations: Abbott Laboratories, Anheuser, Moelis Locations: Catalent

☆ Here are Thursday's biggest analyst calls: Nvidia, Amazon, Target, DoorDash, Intel, Plug Power & more
▼ + stars: | 2023-11-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Bank of America reiterates Roblox as buy Bank of America said the stock is becoming "more investable." Deutsche Bank initiates Wayfair as buy Deutsche said in its initiation of the stock that it's a "pure-play e-commerce leader." Deutsche Bank initiates DoorDash as buy Deutsche said in its initiation of the company that it has "superior unit economics." Bank of America initiates Gen Digital as buy Bank of America said it likes the cyber safety vendor. Goldman Sachs reiterates Amazon as buy Goldman said it sees an "underappreciated secular growth opportunity" for Amazon shares into next year. "

Persons: it's, Goldman Sachs, Goldman, 1QFY, Roblox, Price, Stifel, Baird, Catalent, 1HCY24, Piper Sandler, Piper, Philip Morris, Guggenheim, Wells, TD Cowen downgrades Organizations: UBS, Nvidia, Qs, Networks, Palo Alto Networks, 1QFY billings, billings, Bank of America, Products, Deutsche Bank, Deutsche, HSBC downgrades Altice, HSBC, Goodyear Tire, Goodyear, " Bank of America, ITT, of America, Aerospace & Defense, Digital, JPMorgan, Entertainment, Mizuho, Intel, AMD, Amazon, Citi, EV, TD Cowen downgrades Target Locations: HSBC downgrades Altice USA, China

☆ Stocks making the biggest moves midday: Target, Expedia, Generac, Catalent and more
▼ + stars: | 2023-11-15 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Target — Shares of the retailer surged 17% after Target's fiscal third-quarter earnings came in much stronger than expected. Generac — The power generator company jumped almost 4% after Bank of America upgraded shares to neutral from underperform by Bank of America. The firm cut its price target on the stock, however, and lowered its 2024 earnings estimates on the company. Catalent — The pharmaceuticals company jumped 12% Wednesday after posting a narrower-than-expected loss per share and a revenue beat in the fiscal first quarter. American Eagle Outfitters — Shares of the retailer rose 5% after Bank of America upgraded the company to neutral from underperform.

Persons: Holley —, Michael Lasser, Generac, Berkshire Hathaway, Catalent, — CNBC's Michelle Fox, Jesse Pound, Sarah Min, Pia Singh, Alex Harring Organizations: Jefferies, —, Corp, JPMorgan, Reuters, ValueAct Capital Management, UBS, Bank of America, Disney —, Deutsche Bank, JD.com, Sirius XM —, Berkshire, American Eagle Outfitters Locations: underperform

☆ Morning Bid: Inflation on the ropes, shutdown averted
▼ + stars: | 2023-11-15 | by ( ) www.reuters.com time to read: +5 min

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 26, 2023. Much like then, the sheer scale of the yield swoon has stoked bond volatility gauges (.MOVE) too. What's more, a quarter point rate cut by May is now 80% priced and 100bps of easing through 2024 is now baked in. U.S. corporate news stays on retail later as Target reports earnings, following a beat by Home Depot on Tuesday. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Brendan McDermid, Mike Dolan, Xi Jinping's, Joe Biden, Russell, Austan Goolsbee, Berkshire Hathaway, Warren Buffett, Michael Barr, Thomas Barkin, Jonathan Haskel, Xi Jinping, Bernadette Baum Organizations: New York Stock Exchange, REUTERS, Wall, Chicago Fed, Bank of America, Home Depot, Berkshire, General Motors, Procter, Gamble, Richmond Fed, Bank of England, APEC, Cisco Systems, Palo Alto Networks, Reuters, NFIB, Reuters Graphics Reuters, Thomson Locations: New York City, U.S, Wall, UK's, York, San Francisco

☆ Beware these companies due to report earnings that have negative profit momentum
▼ + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

CNBC Pro screened for the S & P 500 companies still reporting next week that analysts have expressed the most caution on — by cutting their earnings estimates ahead of the reports. Analyst consensus earnings estimates are down at least 5% over the past three months. Analyst consensus earnings estimates are down at least 5% over the past six months. CTLT YTD mountain Catalent YTD chart "Catalent (CTLT) became a very noticeable laggard in the life science space about fifteen months ago. Meat producer Tyson Foods , which is due to report earnings premarket on November 13, was also among the stocks with negative earnings momentum.

Persons: Gordon Haskett, Don Bilson, Bilson, Catalent, Michael Lasser, Lasser, Morgan Stanley, BBWI, Alex Straton, Tyson Foods, — CNBC's Michael Bloom Organizations: CNBC Pro, Biotechnology, Sarepta Therapeutics, Dystrophy, UBS, 3Q, Body Locations: Columbus , Ohio, Bath

☆ Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources
▼ + stars: | 2023-11-07 | by ( Svea Herbst-Bayliss | ) www.reuters.com time to read: +3 min

NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter. Elliott declined to comment, while a representative for BioMarin did not immediately respond to a request for comment. BioMarin shares rose 12% to $85.36 on the news in morning trading in New York on Tuesday. Prior to news of Elliott's engagement, BioMarin shares were down 24% year-to-date, significantly underperforming the iShares Biotechnology ETF (IBB.O), which is down 8.6%. Elliott also successfully pushed for drug makers Alexion Pharma (AZN.L) and Allergan (ABBV.N) to be sold.

Persons: Elliott, BioMarin, hemophilia, Jean, Jacques Bienaime, Alexander Hardy, Jefferies, Bienaime, Harvey, Richard Meier, Svea Herbst, Bayliss, Jamie Freed Organizations: Investment Management, BioMarin Pharmaceutical, Biotechnology, Alexion Pharma, Svea, Thomson Locations: BioMarin, San Rafael , California, West Palm Beach , Florida, New York

☆ Restaurant stocks McDonald's and Chipotle could be due for a pullback after the market's rally this week
▼ + stars: | 2023-11-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

The stock market is enjoying its best week of 2023, but some names may have gotten ahead of themselves. That said, some stocks have become overbought during this week's rally — and could be due for a pullback. MCD YTD mountain McDonald's stock Beverage company Coca-Cola was another one of the several consumer names on this week's overbought list. Here are the 10 most oversold names in the broad market index: Several health-care companies were among this week's most oversold stocks. SEDG 1D mountain SolarEdge shares Revvity, Henry Schein, Align Technology and Fortive are some of the other oversold names from this week.

Persons: McDonald, Kraft Heinz, Amgen, David Palmer, CNBC's, Dr Pepper, SolarEdge, Zvi Lando, Henry Schein Organizations: Dow Jones, Nasdaq, PayPal, Pfizer, CNBC, Beverage, PepsiCo, Monster Beverage, Grill, Darden, Moderna, Enphase Energy, SolarEdge Technologies, Technology Locations: U.S, Europe

☆ How Novo Nordisk makes its weight-loss drug Wegovy
▼ + stars: | 2023-11-01 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

[1/2] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsLONDON, Nov 1 (Reuters) - Novo Nordisk (NOVOb.CO) is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy. FILL-FINISHNovo has hired Catalent (CTLT.N), a large U.S. contract drug manufacturer, to fill injection pens for Wegovy at two of that company's plants: in Brussels and in Bloomington, Indiana. Novo has also hired another U.S. firm, Thermo Fisher (TMO.N), as a Wegovy pen filler. COMPONENTSThe Wegovy injection pens for the U.S. market slightly differ from those sold in the European markets including Norway, Denmark, Germany and UK, where it has so far launched.

Persons: Victoria Klesty, Catalent, Novo, Wegovy, Maggie Fick, Josephine Mason, Tomasz Janowski Organizations: REUTERS, Novo Nordisk, U.S, Novo, Reuters, PCI Pharma Services, autoinjectors, West Pharmaceutical Services, Stevenato, SCHOTT Pharma, Thomson Locations: Oslo, Norway, August31, Victoria, Danish, Novo, Denmark, U.S, Brussels, Bloomington , Indiana, Greenville , North Carolina, Greenville, Germany, Europe, Swiss

Six of the 11 major S&P 500 sectors were trading lower, with information technology (.SPLRCT) leading losses. Pfizer's shares (PFE.N) fell 1.5% after the drugmaker reported its first quarterly loss since 2019. U.S. equities are tracking their third straight month in the red, with the S&P 500 (.SPX) and the Nasdaq (.IXIC) on course for their worst October since 2018. The Fed kicks off a two-day monetary policy meeting on Tuesday. The Fed's commentary on Wednesday would be crucial in assessing how long monetary policy could stay restrictive amid recent signs of economic strength.

Persons: Brendan McDermid, Andrew Hunter, Amruta Khandekar, Shashwat Chauhan, Saumyadeb Chakrabarty, Shounak Dasgupta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Corp, Dow, Nasdaq, Federal, Nvidia, Microsoft, Caterpillar, Chicago PMI, Capital Economics, Dow Jones, PDD Holdings, VF Corp, Vans, Arista Networks, Sarepta Therapeutics, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. "Supply of Wegovy is the most important thing for specialist healthcare investors covering Novo right now," said Barclays analyst Emily Field. Some analysts said a firm date would ease concerns that Novo's supply constraints could allow rival Eli Lilly (LLY.N) to get ahead, when it launches its Mounjaro weight-loss drug. Eli Lilly, the world's most valuable drug company ahead of Novo, has said it expects U.S. approval for the drug, currently licensed for diabetes, to be used for weight loss by the end of the year. Novo is spending billions to increase Wegovy output and hiring more contract manufacturers to fill the pens.

Persons: Victoria Klesty, Wegovy, Novo, Emily Field, Eli Lilly, Markus Manns, Manns, Catalent, Jefferies, Jacob Gronholt, Pedersen, Maggie Fick, Josephine Mason, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wegovy, Barclays, U.S . Food, Drug Administration, Union Investment, Thomson Locations: Oslo, Norway, Victoria, COPENHAGEN, United States, Danish, Germany, Novo, U.S, Brussels, London

☆ Starboard may be poised to build value amicably at contract research firm Fortrea
▼ + stars: | 2023-10-21 | by ( Kenneth Squire | ) www.cnbc.com time to read: +5 min

CROs work with drug companies through all stages of the drug development process, from drug discovery and preclinical development to Phase I through IV post-approval work. With a material portion of that outsourced, the CRO industry has grown accordingly. So, there are strong secular tailwinds driving growth for the CRO industry, but to be a successful contract research organization, it helps to have global scale. With peer margins and peer multiples, Starboard sees this as a $47 to $72 stock. Elliott Management recently partnered with Patient Square Capital and Veritas Capital to acquire Fortrea peer Syneos Health Inc (SYNH) for $7.1 billion.

Persons: Covance, Fortrea, Tom Pike, Pike, Elliott, Ken Squire Organizations: Fortrea, Labcorp, Development, Elliott Management, Square, Veritas Capital, Inc, pharma, 13D, Fortrea Holdings Locations: Covance, Labcorp, Fortrea

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Weight-loss drugs fuel boom for firms that fill syringes
▼ + stars: | 2023-10-09 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

[1/5] Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Eli Lilly's (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year. The U.S. Inflation Reduction Act is also boosting development of biologic drugs, some of which are injected. Injectables are increasingly used in elderly care settings, and some new Alzheimer's and generic arthritis drugs are administered by injection. One healthcare investor said CDMOs' ability to boost capacity will determine how fast the obesity drug market grows.

Persons: Wegovy, it's, Savant, Morgan Stanley, Eli Lilly's, Mounjaro, Chris Chen, Cornell Stamoran, Fujifilm Diosynth, Germany's Vetter, Lilly, Marc Casper, CDMOs, Luke Sergott, Catalent, Catalent's Stamoran, Maggie Fick, Patrick Wingrove, Josephine Mason, Catherine Evans Organizations: REUTERS Acquire, Pfizer, HK, Fujifilm, Fujifilm Corp, Novo, Reuters, Research, Insight Partners, Barclays, Thomson Locations: Brussels, Belgium, Handout, United States, WuXi, Europe, GLP, Anagni, Italy, Bloomington , Indiana, U.S, New York

Search resuls for: "Catalent"

25 mentions found